article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.

article thumbnail

Tapping into pharma’s growing opportunities in digital health

Pharmaceutical Technology

One is at a healthcare provider level, where the latest advances in genetic testing and biomarker measurement have the potential to boost the early detection of conditions and hone decision-making around the most effective treatments. Assessing opportunities in the context of brand strategy. Breaking down the opportunities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Content Marketing Campaigns: How Pharma Brands Engage HCPs & Patients

Pharma Marketing Network

Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharma brands digital presence. Instead of traditional promotional tactics, pharma brands can use educational content to build credibility.

article thumbnail

STAT+: Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million

STAT News

In the life sciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. Pretzel Therapeutics is one of this year’s more creative gambits, launching Monday with $72.5 Continue to STAT+ to read the full story…

article thumbnail

Welcome to 1st Rare & Genetic Neurodegenerative Drug Development Summit

pharmaphorum

Eli Lilly is investing $700M into genetic medicine, announcing plans to establish a Boston research center, and with the acquisition of Prevail Therapeutics in late 2020, Lilly secured access to two gene therapies that had already advanced into human testing — with one targeting Parkinson’s disease and the other, dementia.

article thumbnail

Pfizer drops the blue pill, kicks off 2021 with new DNA logo

pharmaphorum

Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. Encoded within a successful emblem is a company’s DNA – its history, its future.

DNA 116
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

“We also benefit from having cGMP manufacturing capabilities in compliance with global regulatory requirements, a strong heritage from our mother company’s brand, a proven track record of reliable and secure supply, and a new partner that is probably the best player in the market within enzyme diversity.

Drugs 295